SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management will participate in the following virtual investor conference events:
- Cowen 42nd Annual Health Care Conference: The “Auditory and Ophthalmology” panel session on March 7, 2022 at 2:10 p.m. ET / 11:10 a.m. PT;
- Cowen 42nd Annual Health Care Conference: A fireside chat on March 8, 2022 at 1:30 p.m. ET / 10:30 a.m. PT; and
- Oppenheimer 32nd Annual Healthcare Conference: A fireside chat on March 15, 2022 at 11:20 a.m. ET / 8:20 a.m. ET.
Live audio webcasts and archived replays of the events will be available through the Events page of the company's website (www.otonomy.com).
About Otonomy
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information please visit www.otonomy.com.
Contacts:
Media Inquiries:
Spectrum Science
Cate Cullen
Account Director
205.910.4443
ccullen@spectrumscience.com
Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com
